% Expired Patents = 60.0

EPO Patents = 2

Trademarks = 1

Forward Citations = 30

Loading Chart...

1 inventor (with patents filed for the assignee):

Jeffrey L Garwin (5 out of 10 patents)

5 patents: Sort by Forward Citations

1. 8486656 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2013-07-16),

2. 7960138 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2011-06-14),

3. 7670799 - Method for making 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (TCPP) solution and composition comprising TCPP (2010-03-02),

4. 7384764 - Method for prognosing response to cancer therapy with 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2008-06-10),

5. 6838248 - Compositions and methods for detecting pre-cancerous conditions in cell and tissue samples using 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine (2005-01-04),

Biomoda, Inc. is a biotechnology company focused on developing and commercializing cancer diagnostics. Their flagship product, the CyPath® Lung test, uses a patented technology to detect early stage lung cancer by analyzing sputum samples. Biomoda's innovative approach aims to improve early detection rates and ultimately save lives. With a commitment to advancing precision medicine, Biomoda is dedicated to revolutionizing cancer care through cutting-edge technology.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

5 Patents

#83 in Albuquerque, NM

#133 in New Mexico

#51,570 in US

Albuquerque, NM, United States of America

Biomoda, Inc.

Forward Citations = 30

1 inventor:

Jeffrey L Garwin (5 out of 10 patents)

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]